




16. A compound of general formula (II), (III), (IV), (V) or (VI):




general formula (II)




general formula (III)



general formula (IV)



general formula (V)



general formula (VI)

wherein in each of those independent formulas

R^1 , R^2 , R^4 , R^5 , R^6 , and R^7 have the meaning as in any of claims 1 to 9,

R^8 is C_{1-4} alkyl-O-, optionally substituted by 1 or more substituents independently selected from each other from the group of fluoro, chloro, bromo, -CN, C_{1-4} alkyl-O-, C_{1-4} alkyl-, phenyl and benzyl, wherein phenyl and benzyl optionally may be substituted with one or more substituents independently selected from each other from the group of fluoro, chloro, bromo, -CN, C_{1-4} alkyl-O-, C_{1-4} alkyl-; and

PG is a protecting group for an amino function, selected from the group consisting of tert-butoxycarbonyl-, 9-fluorenylmethoxycarbonyl-, benzyl- and 2,4-dimethoxybenzyl-.

17. ~~Use of Method for the treatment of a disease or condition as defined in claim 11 in a patient comprising administering to said patient a therapeutically active amount of a compound according to any one or more of claims 1 to 11 in the manufacture of a medicament for the treatment of a disease or condition selected from the group consisting of (a) a CNS disease, the treatment of which is accessible by the inhibition of GlyT1, (b) a disease that is accessible by the inhibition of GlyT1, (c) a condition selected from the group consisting of positive and negative symptoms of schizophrenia, psychoses and cognitive impairments associated with schizophrenia, Alzheimer's Disease, and psychiatric disorders, (d) Alzheimer's disease or cognitive impairment associated with Alzheimer's disease, (e) schizophrenia or cognitive impairment associated with schizophrenia, and (f) psychoses.~~